Ablation of both organic cation transporter (oct)1 and oct2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics

Drug Metabolism and Disposition

Volumn 40, Issue 6, 2012, Pages 1170-1177

  Higgins, J William ^a   Bedwell, David W ^a   Zamek Gliszczynski, Maciej J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; METFORMIN; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EXCRETION; DRUG EXPOSURE; DRUG TISSUE LEVEL; DRUG URINE LEVEL; GLOMERULUS FILTRATION RATE; KIDNEY; KIDNEY BLOOD FLOW; KNOCKOUT MOUSE; LIVER; MALE; MOUSE; NONHUMAN; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN FUNCTION; WILD TYPE;

ANIMALS; KIDNEY; LIVER; MALE; METFORMIN; MICE; MICE, KNOCKOUT; OCTAMER TRANSCRIPTION FACTOR-1; ORGANIC CATION TRANSPORT PROTEINS; TISSUE DISTRIBUTION;

MUS;

EID: 84862066298     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.044875     Document Type: Article

References (31)

1. Amphoux A, Vialou V, Drescher E, Brüss M, Mannoury La Cour C, Rochat C, Millan MJ, Giros B, Bönisch H, and Gautron S (2006) Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology 50:941-952. (Pubitemid 43810126)
2. Bailey CJ and Turner RC (1996) Metformin. N Engl J Med 334:574-579. (Pubitemid 126537875)
3. Bingham SA and Cummings JH (1985) The use of creatinine output as a check on the completeness of 24-hour urine collections. Hum Nutr Clin Nutr 39:343-353. (Pubitemid 16240308)
4. Chen L, Pawlikowski B, Schlessinger A, More SS, Stryke D, Johns SJ, Portman MA, Chen E, Ferrin TE, Sali A, et al. (2010) Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. Pharmacogenet Genomics 20:687-699.
5. Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK, Urban TJ, Chen L, Yee SW, Choi JH, et al. (2009) Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics 19:497-504.
6. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
7. DeGorter MK and Kim RB (2011) Use of transgenic and knockout mouse models to assess solute carrier transporter function. Clin Pharmacol Ther 89:612-616.
8. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, et al. (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
9. Gründemann D, Gorboulev V, Gambaryan S, Veyhl M, and Koepsell H (1994) Drug excretion mediated by a new prototype of polyspecific transporter. Nature 372:549-552. (Pubitemid 24368536)
10. Jonker JW, Wagenaar E, Mol CA, Buitelaar M, Koepsell H, Smit JW, and Schinkel AH (2001) Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol Cell Biol 21:5471-5477. (Pubitemid 32702451)
11. Jonker JW, Wagenaar E, Van Eijl S, and Schinkel AH (2003) Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol 23:7902-7908. (Pubitemid 37271485)
12. König J, Zolk O, Singer K, Hoffmann C, and Fromm MF (2011) Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations. Br J Pharmacol 163:546-555.
13. Kusuhara H, Ito S, Kumagai Y, Jiang M, Shiroshita T, Moriyama Y, Inoue K, Yuasa H, and Sugiyama Y (2011) Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther 89:837-844.
14. Minematsu T, Iwai M, Umehara K, Usui T, and Kamimura H (2010) Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3- (pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3- d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant. Drug Metab Dispos 38:1-4.
15. Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R, Zanger UM, Keppler D, Schwab M, and Schaeffeler E (2009) Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 50:1227-1240.
16. Nishimura M and Naito S (2005) Tissue-specific mRNA expression profiles of human ATPbinding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet 20:452-477.
17. Saitoh R, Sugano K, Takata N, Tachibana T, Higashida A, Nabuchi Y, and Aso Y (2004) Correction of permeability with pore radius of tight junctions in Caco-2 monolayers improves the prediction of the dose fraction of hydrophilic drugs absorbed by humans. Pharm Res 21:749-755. (Pubitemid 39011295)
18. Schäli C, Schild L, Overney J, and Roch-Ramel F (1983) Secretion of tetraethylammonium by proximal tubules of rabbit kidneys. Am J Physiol 245:F238-F246. (Pubitemid 13031341)
19. Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, Sheardown SA, Yue L, Burchard EG, Brett CM, et al. (2008) Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 83:273-280.
20. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, et al. (2007) Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 117:1422-1431. (Pubitemid 46718430)
21. Somogyi A, Stockley C, Keal J, Rolan P, and Bochner F (1987) Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 23:545-551. (Pubitemid 17087957)
22. Song IS, Shin HJ, Shim EJ, Jung IS, Kim WY, Shon JH, and Shin JG (2008) Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther 84:559-562.
23. Stepensky D, Friedman M, Raz I, and Hoffman A (2002) Pharmacokinetic- pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect. Drug Metab Dispos 30:861-868. (Pubitemid 34815414)
24. Sweet DH and Pritchard JB (1999) rOCT2 is a basolateral potential-driven carrier, not an organic cation/proton exchanger. Am J Physiol 277:F890-F898. (Pubitemid 30046064)
25. Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O, and Inui K (2007) Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol 74:359-371. (Pubitemid 46890818)
26. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, and Sugiyama Y (2002) Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 302:510-515. (Pubitemid 34787213)
27. Wang DS, Kusuhara H, Kato Y, Jonker JW, Schinkel AH, and Sugiyama Y (2003) Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol Pharmacol 63:844-848. (Pubitemid 36368991)
28. Wang ZJ, Yin OQ, Tomlinson B, and Chow MS (2008) OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics 18:637-645.
29. Wilcock C and Bailey CJ (1990) Sites of metformin-stimulated glucose metabolism. Biochem Pharmacol 39:1831-1834. (Pubitemid 20166641)
30. Wilcock C and Bailey CJ (1991) Reconsideration of inhibitory effect of metformin on intestinal glucose absorption. J Pharm Pharmacol 43:120-121.
31. Zamek-Gliszczynski MJ, Kalvass JC, Pollack GM, and Brouwer KL (2009) Relationship between drug/metabolite exposure and impairment of excretory transport function. Drug Metab Dispos 37:386-390.